Social media aggregation site will highlight real-time digital conversations at DIA 2018
Dublin, Ireland, 22 June 2018 – ICON plc, (NASDAQ: ICLR) a global provider of drug development services to the pharmaceutical, biotechnology and medical device industries, today announced that it will present DIA Live – a social media aggregation site that allows visitors to track and analyse Twitter conversations from delegates at the DIA 2018 Global Annual Meeting (24 - 28 June, Boston, MA).
DIA is the largest global interdisciplinary gathering of life sciences professionals, with over 7,000 visitors from over 50 countries. DIA Live will provide a single source for visitors to view the social media conversations from conference participants, alongside broader conversations from Twitter users around the world using the hashtag #DIA2018. DIA Live will launch on the 24 June and will aggregate and stream a live feed of tweets sent by conference delegates as well as other industry participants.
DIA Live features include:
- Real-time view of trending topics, breaking news stories and expert commentary from the conference
- Filtering, by keyword, hashtag, content format or Twitter profile to enable easy personalisation of content
- Ability for visitors to create and publish stories and to engage with the most influential experts in the industry
- For bloggers and media publications, the ability to create and customise widgets that can be easily embedded in other websites, providing a real-time stream of content and infographics from DIA Live
- An interactive timeline that presents activity volumes, key highlights and the ability to review conversations from prior days as the conference progresses
This is the third year that ICON and DIA have collaborated to present DIA Live. In 2017 the platform analysed 3.7K tweets, and almost 4K further shares, from conference delegates discussing a variety of industry topics including big data, patient engagement, clinical trials and healthcare regulation. In total this activity had an audience influence reach of over 26K people.
David Green, VP Marketing, ICON said “We are delighted to continue our collaboration with DIA to help industry professionals join the conversation on a variety of important topics, including disruptive innovation, special patient populations and value and market access. DIA Live combines powerful data analysis and visualisation features to provide a unique digital forum to connect the world’s largest gathering of life sciences professionals.”
“The discussions taking place at the DIA 2018 Global Annual Meeting cover global trends and the most pressing issues impacting the life sciences industry today,” said Elisabeth Svensson, Senior Vice President, Global Marketing & Business Development, DIA. “DIA Live offers a unique digital forum providing attendees and onlookers alike with analysis and valuable insights into these global conversations that are helping to drive the life science ecosystem forward.
To join the 2018 DIA conversation, follow and engage with our team via www.dialive.org
About DIA 2018
DIA 2018 is DIA’s global annual meeting to advance healthcare product development around the world by connecting stakeholders to interdisciplinary insights and innovation. As the organization’s largest interdisciplinary event, DIA 2018 is a gathering of global perspectives bringing together a network of more than 7,000 professionals to foster innovation that leads to the development of safe and effective products and therapies to patients. The global annual meeting will draw attendees from 51 countries for the five-day conference, which also features a three-day expo with more than 450 exhibitors. For more information visit DIAglobal.org/DIA2018 or follow DIA on Twitter, LinkedIn, and Facebook. Join the conversation using #DIA2018.
About ICON plc
ICON plc is a global provider of outsourced drug development and commercialisation services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specializes in the strategic development, management and analysis of programs that support clinical development from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 97 locations in 38 countries and has approximately 13,380 employees.
Further information is available at www.iconplc.com
ICON Media Contact
44-207 067 0557
This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.